Targeting PARP Inhibitor Resistance

Abstract

Various inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the treatment of patients with ovarian cancers defective in homology-directed DNA repair, e.g. due to the loss of BRCA1/2 function. Despite the success of this approved novel therapy, drug resistance is a major clinical hurdle. The overall goal of this project is to target PARPi resistance in BRCA1/2-mutated high-grade serous ovarian cancer (HGS-OvCa), in order to optimize the use of PARPi and to develop new therapeutic approaches to overcome drug resistance.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2023
Accession Number
AD1221329

Entities

People

  • Intidhar Labidi-Galy
  • Sven Rottenberg

Organizations

  • University of Bern

Tags

Fields of Study

  • Medicine

Readers

  • Molecular Biology and Genetics
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech